Sandu Pharmaceuticals Valuation

Q: What is the Fair Price of 524703 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

524703 (₹56.79) is trading above our estimate of [[fair value]] (₹6.47)

Is 524703 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524703 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524703 (₹56.79) is trading above our estimate of fair value (₹6.47)

Significantly Below Fair Value: 524703 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524703?

Key metric: As 524703 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 524703. This is calculated by dividing 524703's market cap by their current earnings.
What is 524703's PE Ratio?
PE Ratio	36.1x
Earnings	₹15.19m
Market Cap	₹548.65m

524703 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	22.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 524703's PE Ratio compare to its peers?

The above table shows the PE ratio for 524703 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	26.1x
WALPAR Walpar Nutritions	17.3x	n/a	₹428.2m
542248 Deccan Health Care	37x	n/a	₹572.2m
530689 Lykis	34.5x	n/a	₹826.2m
531762 Unjha Formulations	15.5x	n/a	₹124.0m
524703 Sandu Pharmaceuticals	36.1x	n/a	₹548.6m

Price-To-Earnings vs Peers: 524703 is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the peer average (26.1x).

Price to Earnings Ratio vs Industry

How does 524703's PE Ratio compare vs other companies in the IN Personal Products Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 524703 is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the Asian Personal Products industry average (24.9x).

Price to Earnings Ratio vs Fair Ratio

What is 524703's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524703 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	36.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524703's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jyothy Labs

₹148.4b

Engages in the manufacture and marketing of fabric care, dishwashing, personal care, and household insecticides products in India and internationally.

JYOTHYLAB

₹404.20

-5.3%

-8.1%

Emami

₹278.9b

Manufactures and markets personal and healthcare products in India and internationally.

EMAMILTD

₹638.85

-0.6%

26.8%

Godrej Consumer Products

₹1.2t

A fast-moving consumer goods company, engages in the manufacture and marketing of personal care and home care products in India, Africa, Indonesia, the Middle East, the United States of America, and internationally.

532424

₹1,193.20

1.5%

18.2%